Global Glucagon research

Glucagon Comprehensive Study by Type (Glucagon Like Peptide 1, Glucagon Like Peptide 2), Application (Hypoglycemia, Radiologic Examination, Cardiogenic Shock, Emergency Kits, Others), End Users (Hospitals, Clinics, Rehabilitation Centers, Others), Form (Injectable, Nasal Powder), Age Group (Pediatric, Adult, Geriatric) Players and Region - Global Market Outlook to 2030

Glucagon Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Glucagon Market Overview:
Glucagon is peptide hormone drug that is highly utilized to treat hypoglycemia and diabetes. In today’s time, the demand for Glucagon Like Peptide 1 is increasing rapidly as it is used to treat type 2 diabetes in the patient. It is increasingly adopted as an emergency medicine for hypoglycemia for the patient who cannot take sugar by mouth as well as a diagnostic aid during X-ray tests of the stomach and bowels. As per latest study released by AMA Research, the Global Glucagon market is expected to see growth rate of 6.6%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Increased Focus on the Research & Development of New Glucagon Formulations to Offer Potentially Easier Delivery

Market Growth Drivers:
Surging Demand of Glucagon as Emergency Medicine to Increase the Level of Blood Glucose in Severe Hypoglycemia and Increasing Use of Glucagon for the Treatment of Patients with Type 1 Diabetes

Challenges:
The Drug Inhibits Movement of the Gastrointestinal (GI) Tract Temporarily and Allergic Reactions in Some People

Restraints:
High Cost Associated with Glucagon May Limit the Adoption in the Rural Areas and Small Hospitals or Clinics

Opportunities:
Rising Number of People with Type 2 Diabetes Due to Change in Lifestyle and Eating Habits and High Application of Glucagon in the Injectable Form by the End Users

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new product launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Torrent Labs (United States), Xeris Pharmaceuticals, Inc. (United States), Pfizer (United States), Novo Nordisk (Denmark), Taj Pharmaceuticals (India), Fresenius Kabi (Germany), Eli Lilly and Company (United States), Mayo Clinic (United States), Amphastar Pharmaceuticals (United States) and Zealand Pharma (Denmark). Analyst at AMA Research see United States Players to retain maximum share of Global Glucagon market by 2030. Considering Market by End Users, the sub-segment i.e. Hospitals will boost the Glucagon market. Considering Market by Form, the sub-segment i.e. Injectable will boost the Glucagon market. Considering Market by Age Group, the sub-segment i.e. Pediatric will boost the Glucagon market.

Latest Market Insights:


In 2021, Zealand Pharma announced the FDA approval of its Zegalogue (dasiglucagon) injection for the treatment of severe hypoglycemia in pediatric and adult patients. The Zegalogue will be available in an auto injector and a prefilled syringe for the treatment. and In 2020, Amphastar Pharmaceuticals, Inc. announced the FDA approval of Glucagon for Injection Emergency Kit, 1 mg. It is used for the treatment of severe hypoglycemia as well as a diagnostic aid. The newly launched synthetic peptide product was determined to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar.

What Can be Explored with the Glucagon Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Glucagon Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Glucagon
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Glucagon market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Glucagon market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Glucagon Manufacturers, Venture Capitalists and Private Equity Firms, Government Bodies and Research Organizations, End-Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Glucagon Like Peptide 1
  • Glucagon Like Peptide 2
By Application
  • Hypoglycemia
  • Radiologic Examination
  • Cardiogenic Shock
  • Emergency Kits
  • Others
By End Users
  • Hospitals
  • Clinics
  • Rehabilitation Centers
  • Others

By Form
  • Injectable
  • Nasal Powder

By Age Group
  • Pediatric
  • Adult
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surging Demand of Glucagon as Emergency Medicine to Increase the Level of Blood Glucose in Severe Hypoglycemia
      • 3.2.2. Increasing Use of Glucagon for the Treatment of Patients with Type 1 Diabetes
    • 3.3. Market Challenges
      • 3.3.1. The Drug Inhibits Movement of the Gastrointestinal (GI) Tract Temporarily and Allergic Reactions in Some People
    • 3.4. Market Trends
      • 3.4.1. Increased Focus on the Research & Development of New Glucagon Formulations to Offer Potentially Easier Delivery
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Glucagon, by Type, Application, End Users, Form, Age Group and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Glucagon (Value)
      • 5.2.1. Global Glucagon by: Type (Value)
        • 5.2.1.1. Glucagon Like Peptide 1
        • 5.2.1.2. Glucagon Like Peptide 2
      • 5.2.2. Global Glucagon by: Application (Value)
        • 5.2.2.1. Hypoglycemia
        • 5.2.2.2. Radiologic Examination
        • 5.2.2.3. Cardiogenic Shock
        • 5.2.2.4. Emergency Kits
        • 5.2.2.5. Others
      • 5.2.3. Global Glucagon by: End Users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Rehabilitation Centers
        • 5.2.3.4. Others
      • 5.2.4. Global Glucagon by: Form (Value)
        • 5.2.4.1. Injectable
        • 5.2.4.2. Nasal Powder
      • 5.2.5. Global Glucagon by: Age Group (Value)
        • 5.2.5.1. Pediatric
        • 5.2.5.2. Adult
        • 5.2.5.3. Geriatric
      • 5.2.6. Global Glucagon Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Australia
          • 5.2.6.2.6. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Glucagon (Price)
      • 5.3.1. Global Glucagon by: Type (Price)
  • 6. Glucagon: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Torrent Labs (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Xeris Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novo Nordisk (Denmark)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Taj Pharmaceuticals (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Fresenius Kabi (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eli Lilly and Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mayo Clinic (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amphastar Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Zealand Pharma (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Glucagon Sale, by Type, Application, End Users, Form, Age Group and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Glucagon (Value)
      • 7.2.1. Global Glucagon by: Type (Value)
        • 7.2.1.1. Glucagon Like Peptide 1
        • 7.2.1.2. Glucagon Like Peptide 2
      • 7.2.2. Global Glucagon by: Application (Value)
        • 7.2.2.1. Hypoglycemia
        • 7.2.2.2. Radiologic Examination
        • 7.2.2.3. Cardiogenic Shock
        • 7.2.2.4. Emergency Kits
        • 7.2.2.5. Others
      • 7.2.3. Global Glucagon by: End Users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Rehabilitation Centers
        • 7.2.3.4. Others
      • 7.2.4. Global Glucagon by: Form (Value)
        • 7.2.4.1. Injectable
        • 7.2.4.2. Nasal Powder
      • 7.2.5. Global Glucagon by: Age Group (Value)
        • 7.2.5.1. Pediatric
        • 7.2.5.2. Adult
        • 7.2.5.3. Geriatric
      • 7.2.6. Global Glucagon Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Australia
          • 7.2.6.2.6. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Glucagon (Price)
      • 7.3.1. Global Glucagon by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Glucagon: by Type(USD Million)
  • Table 2. Glucagon Glucagon Like Peptide 1 , by Region USD Million (2018-2023)
  • Table 3. Glucagon Glucagon Like Peptide 2 , by Region USD Million (2018-2023)
  • Table 4. Glucagon: by Application(USD Million)
  • Table 5. Glucagon Hypoglycemia , by Region USD Million (2018-2023)
  • Table 6. Glucagon Radiologic Examination , by Region USD Million (2018-2023)
  • Table 7. Glucagon Cardiogenic Shock , by Region USD Million (2018-2023)
  • Table 8. Glucagon Emergency Kits , by Region USD Million (2018-2023)
  • Table 9. Glucagon Others , by Region USD Million (2018-2023)
  • Table 10. Glucagon: by End Users(USD Million)
  • Table 11. Glucagon Hospitals , by Region USD Million (2018-2023)
  • Table 12. Glucagon Clinics , by Region USD Million (2018-2023)
  • Table 13. Glucagon Rehabilitation Centers , by Region USD Million (2018-2023)
  • Table 14. Glucagon Others , by Region USD Million (2018-2023)
  • Table 15. Glucagon: by Form(USD Million)
  • Table 16. Glucagon Injectable , by Region USD Million (2018-2023)
  • Table 17. Glucagon Nasal Powder , by Region USD Million (2018-2023)
  • Table 18. Glucagon: by Age Group(USD Million)
  • Table 19. Glucagon Pediatric , by Region USD Million (2018-2023)
  • Table 20. Glucagon Adult , by Region USD Million (2018-2023)
  • Table 21. Glucagon Geriatric , by Region USD Million (2018-2023)
  • Table 22. South America Glucagon, by Country USD Million (2018-2023)
  • Table 23. South America Glucagon, by Type USD Million (2018-2023)
  • Table 24. South America Glucagon, by Application USD Million (2018-2023)
  • Table 25. South America Glucagon, by End Users USD Million (2018-2023)
  • Table 26. South America Glucagon, by Form USD Million (2018-2023)
  • Table 27. South America Glucagon, by Age Group USD Million (2018-2023)
  • Table 28. Brazil Glucagon, by Type USD Million (2018-2023)
  • Table 29. Brazil Glucagon, by Application USD Million (2018-2023)
  • Table 30. Brazil Glucagon, by End Users USD Million (2018-2023)
  • Table 31. Brazil Glucagon, by Form USD Million (2018-2023)
  • Table 32. Brazil Glucagon, by Age Group USD Million (2018-2023)
  • Table 33. Argentina Glucagon, by Type USD Million (2018-2023)
  • Table 34. Argentina Glucagon, by Application USD Million (2018-2023)
  • Table 35. Argentina Glucagon, by End Users USD Million (2018-2023)
  • Table 36. Argentina Glucagon, by Form USD Million (2018-2023)
  • Table 37. Argentina Glucagon, by Age Group USD Million (2018-2023)
  • Table 38. Rest of South America Glucagon, by Type USD Million (2018-2023)
  • Table 39. Rest of South America Glucagon, by Application USD Million (2018-2023)
  • Table 40. Rest of South America Glucagon, by End Users USD Million (2018-2023)
  • Table 41. Rest of South America Glucagon, by Form USD Million (2018-2023)
  • Table 42. Rest of South America Glucagon, by Age Group USD Million (2018-2023)
  • Table 43. Asia Pacific Glucagon, by Country USD Million (2018-2023)
  • Table 44. Asia Pacific Glucagon, by Type USD Million (2018-2023)
  • Table 45. Asia Pacific Glucagon, by Application USD Million (2018-2023)
  • Table 46. Asia Pacific Glucagon, by End Users USD Million (2018-2023)
  • Table 47. Asia Pacific Glucagon, by Form USD Million (2018-2023)
  • Table 48. Asia Pacific Glucagon, by Age Group USD Million (2018-2023)
  • Table 49. China Glucagon, by Type USD Million (2018-2023)
  • Table 50. China Glucagon, by Application USD Million (2018-2023)
  • Table 51. China Glucagon, by End Users USD Million (2018-2023)
  • Table 52. China Glucagon, by Form USD Million (2018-2023)
  • Table 53. China Glucagon, by Age Group USD Million (2018-2023)
  • Table 54. Japan Glucagon, by Type USD Million (2018-2023)
  • Table 55. Japan Glucagon, by Application USD Million (2018-2023)
  • Table 56. Japan Glucagon, by End Users USD Million (2018-2023)
  • Table 57. Japan Glucagon, by Form USD Million (2018-2023)
  • Table 58. Japan Glucagon, by Age Group USD Million (2018-2023)
  • Table 59. India Glucagon, by Type USD Million (2018-2023)
  • Table 60. India Glucagon, by Application USD Million (2018-2023)
  • Table 61. India Glucagon, by End Users USD Million (2018-2023)
  • Table 62. India Glucagon, by Form USD Million (2018-2023)
  • Table 63. India Glucagon, by Age Group USD Million (2018-2023)
  • Table 64. South Korea Glucagon, by Type USD Million (2018-2023)
  • Table 65. South Korea Glucagon, by Application USD Million (2018-2023)
  • Table 66. South Korea Glucagon, by End Users USD Million (2018-2023)
  • Table 67. South Korea Glucagon, by Form USD Million (2018-2023)
  • Table 68. South Korea Glucagon, by Age Group USD Million (2018-2023)
  • Table 69. Australia Glucagon, by Type USD Million (2018-2023)
  • Table 70. Australia Glucagon, by Application USD Million (2018-2023)
  • Table 71. Australia Glucagon, by End Users USD Million (2018-2023)
  • Table 72. Australia Glucagon, by Form USD Million (2018-2023)
  • Table 73. Australia Glucagon, by Age Group USD Million (2018-2023)
  • Table 74. Rest of Asia-Pacific Glucagon, by Type USD Million (2018-2023)
  • Table 75. Rest of Asia-Pacific Glucagon, by Application USD Million (2018-2023)
  • Table 76. Rest of Asia-Pacific Glucagon, by End Users USD Million (2018-2023)
  • Table 77. Rest of Asia-Pacific Glucagon, by Form USD Million (2018-2023)
  • Table 78. Rest of Asia-Pacific Glucagon, by Age Group USD Million (2018-2023)
  • Table 79. Europe Glucagon, by Country USD Million (2018-2023)
  • Table 80. Europe Glucagon, by Type USD Million (2018-2023)
  • Table 81. Europe Glucagon, by Application USD Million (2018-2023)
  • Table 82. Europe Glucagon, by End Users USD Million (2018-2023)
  • Table 83. Europe Glucagon, by Form USD Million (2018-2023)
  • Table 84. Europe Glucagon, by Age Group USD Million (2018-2023)
  • Table 85. Germany Glucagon, by Type USD Million (2018-2023)
  • Table 86. Germany Glucagon, by Application USD Million (2018-2023)
  • Table 87. Germany Glucagon, by End Users USD Million (2018-2023)
  • Table 88. Germany Glucagon, by Form USD Million (2018-2023)
  • Table 89. Germany Glucagon, by Age Group USD Million (2018-2023)
  • Table 90. France Glucagon, by Type USD Million (2018-2023)
  • Table 91. France Glucagon, by Application USD Million (2018-2023)
  • Table 92. France Glucagon, by End Users USD Million (2018-2023)
  • Table 93. France Glucagon, by Form USD Million (2018-2023)
  • Table 94. France Glucagon, by Age Group USD Million (2018-2023)
  • Table 95. Italy Glucagon, by Type USD Million (2018-2023)
  • Table 96. Italy Glucagon, by Application USD Million (2018-2023)
  • Table 97. Italy Glucagon, by End Users USD Million (2018-2023)
  • Table 98. Italy Glucagon, by Form USD Million (2018-2023)
  • Table 99. Italy Glucagon, by Age Group USD Million (2018-2023)
  • Table 100. United Kingdom Glucagon, by Type USD Million (2018-2023)
  • Table 101. United Kingdom Glucagon, by Application USD Million (2018-2023)
  • Table 102. United Kingdom Glucagon, by End Users USD Million (2018-2023)
  • Table 103. United Kingdom Glucagon, by Form USD Million (2018-2023)
  • Table 104. United Kingdom Glucagon, by Age Group USD Million (2018-2023)
  • Table 105. Netherlands Glucagon, by Type USD Million (2018-2023)
  • Table 106. Netherlands Glucagon, by Application USD Million (2018-2023)
  • Table 107. Netherlands Glucagon, by End Users USD Million (2018-2023)
  • Table 108. Netherlands Glucagon, by Form USD Million (2018-2023)
  • Table 109. Netherlands Glucagon, by Age Group USD Million (2018-2023)
  • Table 110. Rest of Europe Glucagon, by Type USD Million (2018-2023)
  • Table 111. Rest of Europe Glucagon, by Application USD Million (2018-2023)
  • Table 112. Rest of Europe Glucagon, by End Users USD Million (2018-2023)
  • Table 113. Rest of Europe Glucagon, by Form USD Million (2018-2023)
  • Table 114. Rest of Europe Glucagon, by Age Group USD Million (2018-2023)
  • Table 115. MEA Glucagon, by Country USD Million (2018-2023)
  • Table 116. MEA Glucagon, by Type USD Million (2018-2023)
  • Table 117. MEA Glucagon, by Application USD Million (2018-2023)
  • Table 118. MEA Glucagon, by End Users USD Million (2018-2023)
  • Table 119. MEA Glucagon, by Form USD Million (2018-2023)
  • Table 120. MEA Glucagon, by Age Group USD Million (2018-2023)
  • Table 121. Middle East Glucagon, by Type USD Million (2018-2023)
  • Table 122. Middle East Glucagon, by Application USD Million (2018-2023)
  • Table 123. Middle East Glucagon, by End Users USD Million (2018-2023)
  • Table 124. Middle East Glucagon, by Form USD Million (2018-2023)
  • Table 125. Middle East Glucagon, by Age Group USD Million (2018-2023)
  • Table 126. Africa Glucagon, by Type USD Million (2018-2023)
  • Table 127. Africa Glucagon, by Application USD Million (2018-2023)
  • Table 128. Africa Glucagon, by End Users USD Million (2018-2023)
  • Table 129. Africa Glucagon, by Form USD Million (2018-2023)
  • Table 130. Africa Glucagon, by Age Group USD Million (2018-2023)
  • Table 131. North America Glucagon, by Country USD Million (2018-2023)
  • Table 132. North America Glucagon, by Type USD Million (2018-2023)
  • Table 133. North America Glucagon, by Application USD Million (2018-2023)
  • Table 134. North America Glucagon, by End Users USD Million (2018-2023)
  • Table 135. North America Glucagon, by Form USD Million (2018-2023)
  • Table 136. North America Glucagon, by Age Group USD Million (2018-2023)
  • Table 137. United States Glucagon, by Type USD Million (2018-2023)
  • Table 138. United States Glucagon, by Application USD Million (2018-2023)
  • Table 139. United States Glucagon, by End Users USD Million (2018-2023)
  • Table 140. United States Glucagon, by Form USD Million (2018-2023)
  • Table 141. United States Glucagon, by Age Group USD Million (2018-2023)
  • Table 142. Canada Glucagon, by Type USD Million (2018-2023)
  • Table 143. Canada Glucagon, by Application USD Million (2018-2023)
  • Table 144. Canada Glucagon, by End Users USD Million (2018-2023)
  • Table 145. Canada Glucagon, by Form USD Million (2018-2023)
  • Table 146. Canada Glucagon, by Age Group USD Million (2018-2023)
  • Table 147. Mexico Glucagon, by Type USD Million (2018-2023)
  • Table 148. Mexico Glucagon, by Application USD Million (2018-2023)
  • Table 149. Mexico Glucagon, by End Users USD Million (2018-2023)
  • Table 150. Mexico Glucagon, by Form USD Million (2018-2023)
  • Table 151. Mexico Glucagon, by Age Group USD Million (2018-2023)
  • Table 152. Glucagon: by Type(USD/Units)
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Glucagon: by Type(USD Million)
  • Table 164. Glucagon Glucagon Like Peptide 1 , by Region USD Million (2025-2030)
  • Table 165. Glucagon Glucagon Like Peptide 2 , by Region USD Million (2025-2030)
  • Table 166. Glucagon: by Application(USD Million)
  • Table 167. Glucagon Hypoglycemia , by Region USD Million (2025-2030)
  • Table 168. Glucagon Radiologic Examination , by Region USD Million (2025-2030)
  • Table 169. Glucagon Cardiogenic Shock , by Region USD Million (2025-2030)
  • Table 170. Glucagon Emergency Kits , by Region USD Million (2025-2030)
  • Table 171. Glucagon Others , by Region USD Million (2025-2030)
  • Table 172. Glucagon: by End Users(USD Million)
  • Table 173. Glucagon Hospitals , by Region USD Million (2025-2030)
  • Table 174. Glucagon Clinics , by Region USD Million (2025-2030)
  • Table 175. Glucagon Rehabilitation Centers , by Region USD Million (2025-2030)
  • Table 176. Glucagon Others , by Region USD Million (2025-2030)
  • Table 177. Glucagon: by Form(USD Million)
  • Table 178. Glucagon Injectable , by Region USD Million (2025-2030)
  • Table 179. Glucagon Nasal Powder , by Region USD Million (2025-2030)
  • Table 180. Glucagon: by Age Group(USD Million)
  • Table 181. Glucagon Pediatric , by Region USD Million (2025-2030)
  • Table 182. Glucagon Adult , by Region USD Million (2025-2030)
  • Table 183. Glucagon Geriatric , by Region USD Million (2025-2030)
  • Table 184. South America Glucagon, by Country USD Million (2025-2030)
  • Table 185. South America Glucagon, by Type USD Million (2025-2030)
  • Table 186. South America Glucagon, by Application USD Million (2025-2030)
  • Table 187. South America Glucagon, by End Users USD Million (2025-2030)
  • Table 188. South America Glucagon, by Form USD Million (2025-2030)
  • Table 189. South America Glucagon, by Age Group USD Million (2025-2030)
  • Table 190. Brazil Glucagon, by Type USD Million (2025-2030)
  • Table 191. Brazil Glucagon, by Application USD Million (2025-2030)
  • Table 192. Brazil Glucagon, by End Users USD Million (2025-2030)
  • Table 193. Brazil Glucagon, by Form USD Million (2025-2030)
  • Table 194. Brazil Glucagon, by Age Group USD Million (2025-2030)
  • Table 195. Argentina Glucagon, by Type USD Million (2025-2030)
  • Table 196. Argentina Glucagon, by Application USD Million (2025-2030)
  • Table 197. Argentina Glucagon, by End Users USD Million (2025-2030)
  • Table 198. Argentina Glucagon, by Form USD Million (2025-2030)
  • Table 199. Argentina Glucagon, by Age Group USD Million (2025-2030)
  • Table 200. Rest of South America Glucagon, by Type USD Million (2025-2030)
  • Table 201. Rest of South America Glucagon, by Application USD Million (2025-2030)
  • Table 202. Rest of South America Glucagon, by End Users USD Million (2025-2030)
  • Table 203. Rest of South America Glucagon, by Form USD Million (2025-2030)
  • Table 204. Rest of South America Glucagon, by Age Group USD Million (2025-2030)
  • Table 205. Asia Pacific Glucagon, by Country USD Million (2025-2030)
  • Table 206. Asia Pacific Glucagon, by Type USD Million (2025-2030)
  • Table 207. Asia Pacific Glucagon, by Application USD Million (2025-2030)
  • Table 208. Asia Pacific Glucagon, by End Users USD Million (2025-2030)
  • Table 209. Asia Pacific Glucagon, by Form USD Million (2025-2030)
  • Table 210. Asia Pacific Glucagon, by Age Group USD Million (2025-2030)
  • Table 211. China Glucagon, by Type USD Million (2025-2030)
  • Table 212. China Glucagon, by Application USD Million (2025-2030)
  • Table 213. China Glucagon, by End Users USD Million (2025-2030)
  • Table 214. China Glucagon, by Form USD Million (2025-2030)
  • Table 215. China Glucagon, by Age Group USD Million (2025-2030)
  • Table 216. Japan Glucagon, by Type USD Million (2025-2030)
  • Table 217. Japan Glucagon, by Application USD Million (2025-2030)
  • Table 218. Japan Glucagon, by End Users USD Million (2025-2030)
  • Table 219. Japan Glucagon, by Form USD Million (2025-2030)
  • Table 220. Japan Glucagon, by Age Group USD Million (2025-2030)
  • Table 221. India Glucagon, by Type USD Million (2025-2030)
  • Table 222. India Glucagon, by Application USD Million (2025-2030)
  • Table 223. India Glucagon, by End Users USD Million (2025-2030)
  • Table 224. India Glucagon, by Form USD Million (2025-2030)
  • Table 225. India Glucagon, by Age Group USD Million (2025-2030)
  • Table 226. South Korea Glucagon, by Type USD Million (2025-2030)
  • Table 227. South Korea Glucagon, by Application USD Million (2025-2030)
  • Table 228. South Korea Glucagon, by End Users USD Million (2025-2030)
  • Table 229. South Korea Glucagon, by Form USD Million (2025-2030)
  • Table 230. South Korea Glucagon, by Age Group USD Million (2025-2030)
  • Table 231. Australia Glucagon, by Type USD Million (2025-2030)
  • Table 232. Australia Glucagon, by Application USD Million (2025-2030)
  • Table 233. Australia Glucagon, by End Users USD Million (2025-2030)
  • Table 234. Australia Glucagon, by Form USD Million (2025-2030)
  • Table 235. Australia Glucagon, by Age Group USD Million (2025-2030)
  • Table 236. Rest of Asia-Pacific Glucagon, by Type USD Million (2025-2030)
  • Table 237. Rest of Asia-Pacific Glucagon, by Application USD Million (2025-2030)
  • Table 238. Rest of Asia-Pacific Glucagon, by End Users USD Million (2025-2030)
  • Table 239. Rest of Asia-Pacific Glucagon, by Form USD Million (2025-2030)
  • Table 240. Rest of Asia-Pacific Glucagon, by Age Group USD Million (2025-2030)
  • Table 241. Europe Glucagon, by Country USD Million (2025-2030)
  • Table 242. Europe Glucagon, by Type USD Million (2025-2030)
  • Table 243. Europe Glucagon, by Application USD Million (2025-2030)
  • Table 244. Europe Glucagon, by End Users USD Million (2025-2030)
  • Table 245. Europe Glucagon, by Form USD Million (2025-2030)
  • Table 246. Europe Glucagon, by Age Group USD Million (2025-2030)
  • Table 247. Germany Glucagon, by Type USD Million (2025-2030)
  • Table 248. Germany Glucagon, by Application USD Million (2025-2030)
  • Table 249. Germany Glucagon, by End Users USD Million (2025-2030)
  • Table 250. Germany Glucagon, by Form USD Million (2025-2030)
  • Table 251. Germany Glucagon, by Age Group USD Million (2025-2030)
  • Table 252. France Glucagon, by Type USD Million (2025-2030)
  • Table 253. France Glucagon, by Application USD Million (2025-2030)
  • Table 254. France Glucagon, by End Users USD Million (2025-2030)
  • Table 255. France Glucagon, by Form USD Million (2025-2030)
  • Table 256. France Glucagon, by Age Group USD Million (2025-2030)
  • Table 257. Italy Glucagon, by Type USD Million (2025-2030)
  • Table 258. Italy Glucagon, by Application USD Million (2025-2030)
  • Table 259. Italy Glucagon, by End Users USD Million (2025-2030)
  • Table 260. Italy Glucagon, by Form USD Million (2025-2030)
  • Table 261. Italy Glucagon, by Age Group USD Million (2025-2030)
  • Table 262. United Kingdom Glucagon, by Type USD Million (2025-2030)
  • Table 263. United Kingdom Glucagon, by Application USD Million (2025-2030)
  • Table 264. United Kingdom Glucagon, by End Users USD Million (2025-2030)
  • Table 265. United Kingdom Glucagon, by Form USD Million (2025-2030)
  • Table 266. United Kingdom Glucagon, by Age Group USD Million (2025-2030)
  • Table 267. Netherlands Glucagon, by Type USD Million (2025-2030)
  • Table 268. Netherlands Glucagon, by Application USD Million (2025-2030)
  • Table 269. Netherlands Glucagon, by End Users USD Million (2025-2030)
  • Table 270. Netherlands Glucagon, by Form USD Million (2025-2030)
  • Table 271. Netherlands Glucagon, by Age Group USD Million (2025-2030)
  • Table 272. Rest of Europe Glucagon, by Type USD Million (2025-2030)
  • Table 273. Rest of Europe Glucagon, by Application USD Million (2025-2030)
  • Table 274. Rest of Europe Glucagon, by End Users USD Million (2025-2030)
  • Table 275. Rest of Europe Glucagon, by Form USD Million (2025-2030)
  • Table 276. Rest of Europe Glucagon, by Age Group USD Million (2025-2030)
  • Table 277. MEA Glucagon, by Country USD Million (2025-2030)
  • Table 278. MEA Glucagon, by Type USD Million (2025-2030)
  • Table 279. MEA Glucagon, by Application USD Million (2025-2030)
  • Table 280. MEA Glucagon, by End Users USD Million (2025-2030)
  • Table 281. MEA Glucagon, by Form USD Million (2025-2030)
  • Table 282. MEA Glucagon, by Age Group USD Million (2025-2030)
  • Table 283. Middle East Glucagon, by Type USD Million (2025-2030)
  • Table 284. Middle East Glucagon, by Application USD Million (2025-2030)
  • Table 285. Middle East Glucagon, by End Users USD Million (2025-2030)
  • Table 286. Middle East Glucagon, by Form USD Million (2025-2030)
  • Table 287. Middle East Glucagon, by Age Group USD Million (2025-2030)
  • Table 288. Africa Glucagon, by Type USD Million (2025-2030)
  • Table 289. Africa Glucagon, by Application USD Million (2025-2030)
  • Table 290. Africa Glucagon, by End Users USD Million (2025-2030)
  • Table 291. Africa Glucagon, by Form USD Million (2025-2030)
  • Table 292. Africa Glucagon, by Age Group USD Million (2025-2030)
  • Table 293. North America Glucagon, by Country USD Million (2025-2030)
  • Table 294. North America Glucagon, by Type USD Million (2025-2030)
  • Table 295. North America Glucagon, by Application USD Million (2025-2030)
  • Table 296. North America Glucagon, by End Users USD Million (2025-2030)
  • Table 297. North America Glucagon, by Form USD Million (2025-2030)
  • Table 298. North America Glucagon, by Age Group USD Million (2025-2030)
  • Table 299. United States Glucagon, by Type USD Million (2025-2030)
  • Table 300. United States Glucagon, by Application USD Million (2025-2030)
  • Table 301. United States Glucagon, by End Users USD Million (2025-2030)
  • Table 302. United States Glucagon, by Form USD Million (2025-2030)
  • Table 303. United States Glucagon, by Age Group USD Million (2025-2030)
  • Table 304. Canada Glucagon, by Type USD Million (2025-2030)
  • Table 305. Canada Glucagon, by Application USD Million (2025-2030)
  • Table 306. Canada Glucagon, by End Users USD Million (2025-2030)
  • Table 307. Canada Glucagon, by Form USD Million (2025-2030)
  • Table 308. Canada Glucagon, by Age Group USD Million (2025-2030)
  • Table 309. Mexico Glucagon, by Type USD Million (2025-2030)
  • Table 310. Mexico Glucagon, by Application USD Million (2025-2030)
  • Table 311. Mexico Glucagon, by End Users USD Million (2025-2030)
  • Table 312. Mexico Glucagon, by Form USD Million (2025-2030)
  • Table 313. Mexico Glucagon, by Age Group USD Million (2025-2030)
  • Table 314. Glucagon: by Type(USD/Units)
  • Table 315. Research Programs/Design for This Report
  • Table 316. Key Data Information from Secondary Sources
  • Table 317. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Glucagon: by Type USD Million (2018-2023)
  • Figure 5. Global Glucagon: by Application USD Million (2018-2023)
  • Figure 6. Global Glucagon: by End Users USD Million (2018-2023)
  • Figure 7. Global Glucagon: by Form USD Million (2018-2023)
  • Figure 8. Global Glucagon: by Age Group USD Million (2018-2023)
  • Figure 9. South America Glucagon Share (%), by Country
  • Figure 10. Asia Pacific Glucagon Share (%), by Country
  • Figure 11. Europe Glucagon Share (%), by Country
  • Figure 12. MEA Glucagon Share (%), by Country
  • Figure 13. North America Glucagon Share (%), by Country
  • Figure 14. Global Glucagon: by Type USD/Units (2018-2023)
  • Figure 15. Global Glucagon share by Players 2023 (%)
  • Figure 16. Global Glucagon share by Players (Top 3) 2023(%)
  • Figure 17. Global Glucagon share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Torrent Labs (United States) Revenue, Net Income and Gross profit
  • Figure 20. Torrent Labs (United States) Revenue: by Geography 2023
  • Figure 21. Xeris Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Xeris Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer (United States) Revenue: by Geography 2023
  • Figure 25. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 26. Novo Nordisk (Denmark) Revenue: by Geography 2023
  • Figure 27. Taj Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 28. Taj Pharmaceuticals (India) Revenue: by Geography 2023
  • Figure 29. Fresenius Kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Fresenius Kabi (Germany) Revenue: by Geography 2023
  • Figure 31. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 33. Mayo Clinic (United States) Revenue, Net Income and Gross profit
  • Figure 34. Mayo Clinic (United States) Revenue: by Geography 2023
  • Figure 35. Amphastar Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amphastar Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 37. Zealand Pharma (Denmark) Revenue, Net Income and Gross profit
  • Figure 38. Zealand Pharma (Denmark) Revenue: by Geography 2023
  • Figure 39. Global Glucagon: by Type USD Million (2025-2030)
  • Figure 40. Global Glucagon: by Application USD Million (2025-2030)
  • Figure 41. Global Glucagon: by End Users USD Million (2025-2030)
  • Figure 42. Global Glucagon: by Form USD Million (2025-2030)
  • Figure 43. Global Glucagon: by Age Group USD Million (2025-2030)
  • Figure 44. South America Glucagon Share (%), by Country
  • Figure 45. Asia Pacific Glucagon Share (%), by Country
  • Figure 46. Europe Glucagon Share (%), by Country
  • Figure 47. MEA Glucagon Share (%), by Country
  • Figure 48. North America Glucagon Share (%), by Country
  • Figure 49. Global Glucagon: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Torrent Labs (United States)
  • Xeris Pharmaceuticals, Inc. (United States)
  • Pfizer (United States)
  • Novo Nordisk (Denmark)
  • Taj Pharmaceuticals (India)
  • Fresenius Kabi (Germany)
  • Eli Lilly and Company (United States)
  • Mayo Clinic (United States)
  • Amphastar Pharmaceuticals (United States)
  • Zealand Pharma (Denmark)
Select User Access Type

Key Highlights of Report


Feb 2024 225 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Glucagon research Quantitative research analysis
Global Glucagon research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Glucagon market are Torrent Labs (United States), Xeris Pharmaceuticals, Inc. (United States), Pfizer (United States), Novo Nordisk (Denmark), Taj Pharmaceuticals (India), Fresenius Kabi (Germany), Eli Lilly and Company (United States), Mayo Clinic (United States), Amphastar Pharmaceuticals (United States) and Zealand Pharma (Denmark), to name a few.
"Increased Focus on the Research & Development of New Glucagon Formulations to Offer Potentially Easier Delivery" is seen as one of major influencing trends for Glucagon Market during projected period 2023-2030.
Glucagon Like Peptide 1 segment in Global market to hold robust market share owing to "Surging Demand of Glucagon as Emergency Medicine to Increase the Level of Blood Glucose in Severe Hypoglycemia ".

Know More About Global Glucagon research Report?

Have a Query? Click Here

Other Related Reports

Herceptin Biosimilar Comprehensive Study by Type (Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera), Application (Anti-Arthritis Drugs, Anti-Cancer Drugs, Respiratory Products, Anti-Infective Drugs, C...
$ 3750
Hyaluronic Acid Comprehensive Study by Type (Single-Injection, Three-Injection Cycle, Five-Injection Cycle), Application (Anti-Aging Treatments, Nutritional Supplements, Medical Treatments, Others), ...
$ 3450
Tecentriq Comprehensive Study by Application (Lung Problems, Intestinal Problems, Liver Problems, Hormone Gland Problems, Kidney Problems, Skin Problems, Others), End User (Hospital, Clinic, Others)...
$ 3500
Fluconazole Comprehensive Study by Distribution Channel (Offline (Hospital, Retail Pharmacy), Online Pharmacy), Form Type (Injectable, Powder, Tablet) Players and Region - Global Market Outlook to 20...
$ 3500
Cancer Antibody Drug Conjugates Comprehensive Study by Type (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others), Technology (Immunogen Technology, Seattle Genetics Technol...
$ 3450
Morphine Comprehensive Study by Application (Arthritis, Diarrhea, Pain Relief, Cancer, Others), Forms (Solid, Liquid), Route of Administration (Oral, Parenteral, Intravenous, Others), Distribution Ch...
$ 3800